Telesis Bio, Inc. (TBIO)

Market Cap	1.80K -100.0%
Revenue (ttm)	17.03M -32.5%
Net Income	-47.93M
EPS	-28.02
Shares Out	1.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	532
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.3000
Beta	2.30
RSI	31.33
Earnings Date	Mar 27, 2026

About Telesis Bio

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: TBIO

Financial Performance

In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.